MaxCyte, Inc. ASGCT Presentation on First CARMA Drug Candidate
01 May 2019 - 4:01PM
RNS Non-Regulatory
TIDMMXCT
MaxCyte, Inc.
01 May 2019
MaxCyte Presents at 22(nd) Annual ASGCT Meeting on Manufacturing
Process for First CARMA(TM) Drug Candidate, Including One-Day Cell
Processing
- CARMA drug candidates can be manufactured via streamlined,
single-day process, providing a much needed faster turnaround of
autologous cell therapy to patients
- CARMA cell therapies are engineered with the intention of
reducing potential adverse events that have been evident with other
CAR technologies and to allow for multiple dosing, an important
feature for potential treatment of solid tumors
Gaithersburg, Maryland - May 1, 2019: MaxCyte (LSE: MXCT, MXCS),
the global clinical-stage cell-based therapies and life sciences
company, announced that Robert Keefe, Director of Technical
Operations, provided an oral presentation on April 29, titled
"Novel mRNA-based Autologous CAR Therapies in Oncology," at the
annual meeting of the American Society of Gene and Cell Therapy
(ASGCT) in Washington, DC.
Dr. Keefe highlighted the CARMA platform's key differentiating
features, including manufacture and delivery to a patient in a
fraction of the time compared to traditional chimeric antigen
receptor (CAR) therapies and without a viral component. He also
described the manufacturing feasibility data for MaxCyte's first
CARMA drug candidate, MCY-M11, a mesothelin-targeting chimeric
antigen receptor (CAR), which is currently being evaluated in a
Phase I clinical trial in mesothelin-expressing solid tumors at the
National Cancer Institute (NCI) and Washington University in St
Louis.
"The advancement of our first CARMA clinical trial, which is
consistently showing the feasibility of our rapid manufacturing
process, is significant for MaxCyte and the application of our
technology," said Claudio Dansky Ullmann, MD, MaxCyte's Chief
Medical Officer. "Development of a cell therapy with application in
solid tumors is impactful for patients with unmet needs in a
variety of cancers and we look forward to further advancing this
program."
The CARMA platform offers an innovative approach to cell-based
therapies that can be applied in a broad range of diseases,
including solid tumors. The manufacturing process for MCY-M11
utilizes MaxCyte's proprietary Flow Electroporation(R) technology
to transfect mRNA into fresh (i.e., unexpanded) peripheral blood
mononuclear cells (PBMCs). The entire CARMA manufacturing process
allows for streamlined manufacturing providing a much needed faster
turnaround of autologous cell therapy to patients. CARMA cell
therapy was engineered with the intention of reducing potential
adverse events that have been evident with other CAR technologies,
and allowing for multiple dosing, a feature that may be key in the
treatment of solid tumors with cellular therapies.
Last month, this trial was featured as a "trial in progress" at
the American Association for Cancer Research (AACR) Annual Meeting
, via a poster highlighting key aspects of the study design.
Dr. Keefe's ASGCT abstract (#74) can be found at the meeting's
website, on page 40 of the PDF, at:
https://www.asgct.org/global/documents/asgct19_abstracts_-final
About MaxCyte
MaxCyte is a clinical-stage global cell-based medicines and life
sciences company applying its proprietary cell engineering platform
to deliver the advances of cell-based medicine to patients with
high unmet medical needs. MaxCyte is developing novel CARMA
therapies for its own pipeline, with its first drug candidate in a
Phase I clinical trial. CARMA is MaxCyte's mRNA-based proprietary
therapeutic platform for autologous cell therapy for the treatment
of solid cancers. In addition, through its life sciences business,
MaxCyte leverages its Flow Electroporation Technology to enable its
biopharmaceutical partners to advance the development of innovative
medicines, particularly in cell therapy. MaxCyte has placed its
flow electroporation instruments worldwide, with all of the top ten
global biopharmaceutical companies. The Company now has more than
70 partnered program licenses in cell therapy with more than 35
licensed for clinical use, including four announced commercial
licenses covering potentially more than 30 products with aggregate
potential milestones of more than $250m. With its robust delivery
technology platform, MaxCyte helps its partners to unlock the full
potential of their products. For more information, visit
www.maxcyte.com.
For further information, please contact:
MaxCyte Inc.
Doug Doerfler, Chief Executive Officer
Claudio Dansky Ullmann, Chief Medical
Officer +1 301 944 1660
Financial PR Adviser
Consilium Strategic Communications +44 (0)203 709 5700
Mary-Jane Elliott maxcyte@consilium-comms.com
Chris Welsh
Sukaina Virji
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
NRAUROARKNASOUR
(END) Dow Jones Newswires
May 01, 2019 02:01 ET (06:01 GMT)
Maxcyte (LSE:MXCT)
Historical Stock Chart
From Apr 2024 to May 2024
Maxcyte (LSE:MXCT)
Historical Stock Chart
From May 2023 to May 2024